Literature DB >> 16940106

Inhibition of fungal beta-1,3-glucan synthase and cell growth by HM-1 killer toxin single-chain anti-idiotypic antibodies.

Dakshnamurthy Selvakumar1, Masahiko Miyamoto, Yasuhiro Furuichi, Tadazumi Komiyama.   

Abstract

Single-chain variable-fragment (scFv) anti-idiotypic antibodies of an HM-1 killer toxin (HM-1) from the yeast Williopsis saturnus var. mrakii IFO 0895 have been produced by recombinant DNA technology from the splenic lymphocytes of mice immunized by idiotypic vaccination with a neutralizing monoclonal antibody (nMAb-KT). The fungicidal activity of scFv anti-idiotypic antibodies against the isolates of four Candida species was assessed by MIC analysis. scFv antibodies were fungicidal at concentrations of 1.56 to 12.5 microg/ml in vitro against four Candida species. The scFv antibodies exerted a strong candidacidal activity in vitro, with 50% inhibitory concentration (IC(50)) values ranging from 7.3 x 10(-8) to 16.0 x 10(-8) M, and were neutralized by adsorption with nMAb-KT. Furthermore, all scFv antibodies effectively inhibited fungal beta-1,3-glucan synthase activity in vitro, with IC(50) values ranging from 2.0 x 10(-8) to 22.7 x 10(-8) M, values which almost coincide with the values that are inhibitory to the growth of fungal cells. Binding assays showed that the scFv antibodies specifically bind to nMAb-KT, and this binding pattern was confirmed by surface plasmon resonance analysis. The binding ability was further demonstrated by the competition observed between scFv antibodies and HM-1 to bind nMAb-KT. To the best of our knowledge, this is the first study to show that an antifungal anti-idiotypic antibody, in the form of recombinant scFv, potentially inhibits beta-1,3-glucan synthase activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940106      PMCID: PMC1563539          DOI: 10.1128/AAC.01435-05

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  56 in total

1.  Emerging novel antifungal agents.

Authors: 
Journal:  Drug Discov Today       Date:  2000-01       Impact factor: 7.851

2.  Identification and characterization of a neutralizing monoclonal antibody for the epitope on HM-1 killer toxin.

Authors:  Dakshnamurthy Selvakumar; Qing-Zhu Zhang; Masahiko Miyamoto; Yasuhiro Furuichi; Tadazumi Komiyama
Journal:  J Biochem       Date:  2006-03       Impact factor: 3.387

3.  High rate of non-albicans candidemia in Brazilian tertiary care hospitals.

Authors:  A L Colombo; M Nucci; R Salomão; M L Branchini; R Richtmann; A Derossi; S B Wey
Journal:  Diagn Microbiol Infect Dis       Date:  1999-08       Impact factor: 2.803

4.  Cell wall synthesis specific cytocidal effect of Hansenula mrakii toxin-1 on Saccharomyces cerevisiae.

Authors:  T Takasuka; T Komiyama; Y Furuichi; T Watanabe
Journal:  Cell Mol Biol Res       Date:  1995

5.  Towards a network theory of the immune system.

Authors:  N K Jerne
Journal:  Ann Immunol (Paris)       Date:  1974-01

6.  Autoantibody to heat-shock protein 90 can mediate protection against systemic candidosis.

Authors:  R C Matthews; J P Burnie; D Howat; T Rowland; F Walton
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

7.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.

Authors:  M H Nguyen; J E Peacock; A J Morris; D C Tanner; M L Nguyen; D R Snydman; M M Wagener; M G Rinaldi; V L Yu
Journal:  Am J Med       Date:  1996-06       Impact factor: 4.965

Review 8.  Antifungal drug targets: Candida secreted aspartyl protease and fungal wall beta-glucan synthesis.

Authors:  R C Goldman; D J Frost; J O Capobianco; S Kadam; R R Rasmussen; C Abad-Zapatero
Journal:  Infect Agents Dis       Date:  1995-12

9.  Strain differentiation of pathogenic yeasts by the killer system.

Authors:  G Morace; C Archibusacci; M Sestito; L Polonelli
Journal:  Mycopathologia       Date:  1984-02-15       Impact factor: 2.574

10.  A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities.

Authors:  María D Moragues; Miren J Omaetxebarria; Natalia Elguezabal; María J Sevilla; Stefania Conti; Luciano Polonelli; José Pontón
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

View more
  7 in total

1.  Antibody Peptide based antifungal immunotherapy.

Authors:  Walter Magliani; Stefania Conti; Laura Giovati; Pier Paolo Zanello; Martina Sperindè; Tecla Ciociola; Luciano Polonelli
Journal:  Front Microbiol       Date:  2012-06-01       Impact factor: 5.640

2.  An improved phage-display panning method to produce an HM-1 killer toxin anti-idiotypic antibody.

Authors:  M Enamul Kabir; Senthilkumar Krishnaswamy; Masahiko Miyamoto; Yasuhiro Furuichi; Tadazumi Komiyama
Journal:  BMC Biotechnol       Date:  2009-12-14       Impact factor: 2.563

3.  KRE5 Suppression Induces Cell Wall Stress and Alternative ER Stress Response Required for Maintaining Cell Wall Integrity in Candida glabrata.

Authors:  Yutaka Tanaka; Masato Sasaki; Fumie Ito; Toshio Aoyama; Michiyo Sato-Okamoto; Azusa Takahashi-Nakaguchi; Hiroji Chibana; Nobuyuki Shibata
Journal:  PLoS One       Date:  2016-08-22       Impact factor: 3.240

Review 4.  Bioprotective Role of Yeasts.

Authors:  Serena Muccilli; Cristina Restuccia
Journal:  Microorganisms       Date:  2015-10-10

Review 5.  Monoclonal Antibodies and Antibody Like Fragments Derived from Immunised Phage Display Libraries.

Authors:  Obinna Ubah; Soumya Palliyil
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

6.  Paeonol Disrupts the Integrity of Aspergillus flavus Cell Walls via Releasing Surface Proteins, Inhibiting the Biosynthesis of β-1,3-Glucan and Promoting the Degradation of Chitin, and an Identification of Cell Surface Proteins.

Authors:  Qian Li; Ying Zhao; Yanli Xie
Journal:  Foods       Date:  2021-12-01

Review 7.  Wickerhamomyces Yeast Killer Toxins' Medical Applications.

Authors:  Laura Giovati; Tecla Ciociola; Tiziano De Simone; Stefania Conti; Walter Magliani
Journal:  Toxins (Basel)       Date:  2021-09-15       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.